AML MRD Detection via Protein Marker Panel and tSNE
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML) are limited by low sensitivity and require significant expertise, as standard flow cytometric monitoring often fails to detect leukemia-specific markers, leading to unreliable results and limited applicability.
Innovation Solution
The use of specific protein markers such as CD9, CD32, CD44, CD52, CD54, CD59, CD64, CD86, CD93, CD96, CD97, CD99, CD123, CX3CR1, and Tim-3 for detecting minimal residual disease through flow cytometry, along with a t-Distributed Stochastic Neighbor Embedding (tSNE) machine learning algorithm for enhanced sensitivity and reliability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard flow cytometric monitoring is used to detect MRD in AML, then the method is simple and widely applicable, but the sensitivity is low and reliability is poor
Solution Approach 1:
The patent changes the detection parameters by using a specific panel of 7 protein markers (CD13, CD33, CD117, HLA-DR, CD7, CD14, CD19) that are aberrantly expressed in AML cells. This parameter change enables detection of one leukemic cell among 100,000 normal cells, dramatically improving sensitivity from standard methods while maintaining flow cytometry's relative simplicity
Solution Approach 2:
The patent creates a universal MRD detection panel that can identify AML cells across different leukemic subtypes by targeting protein markers that are commonly aberrantly expressed in AML. This multi-functional marker panel applies to various AML cases regardless of specific genetic abnormalities, making the method widely applicable while achieving high sensitivity
2Reliability
If conventional morphologic analysis is used to identify leukemic cells, then the analysis is straightforward, but it cannot distinguish chemo-resistant leukemic cells from normal hematopoietic progenitors
Solution Approach 1:
The patent applies local quality by focusing detection on specific protein marker expressions rather than attempting to analyze all cellular characteristics. The flow cytometry method measures the presence and levels of specific proteins (CD13, CD33, CD117, etc.) on cell surfaces, providing localized molecular identification that reliably distinguishes leukemic cells from normal progenitors based on their unique protein expression patterns
3Measurement precision
If PCR amplification of genetic abnormalities is used to detect MRD, then genetic information can be obtained, but the method is complex and not applicable to all AML cases
Solution Approach 1:
The patent creates a universal detection system using protein markers that are aberrantly expressed across different AML subtypes. Unlike PCR methods that require specific genetic abnormalities (which are present in only about 50% of AML cases), this flow cytometry-based approach using 7 specific markers can detect MRD in virtually all AML patients, significantly improving adaptability while maintaining high sensitivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the detection of MRD in AML by increasing sensitivity and reliability, allowing for the visualization of one leukemic cell among more than 100,000 normal cells, thereby refining treatment strategies and providing new criteria for studying novel agents.
Implementation Method 1
Each probe specifically binds to a single marker
Data Source
AI summary
Methods for detecting the presence of proteins in a subject are described. The proteins detected can be indicative of acute myeloid leukemia (AML). The proteins can be particularly useful for monitoring minimal residual disease (MRD) in AML.